Wellington Management Group’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.27M Buy
313,005
+107,260
+52% +$1.19M ﹤0.01% 1513
2026
Q2
$2.12M Buy
+205,745
New +$1.55M ﹤0.01% 1613
2025
Q4
– Sell
-137,888
Closed -$703K – 1940
2025
Q3
$703K Buy
137,888
+51,641
+60% +$298K ﹤0.01% 1840
2025
Q2
$436K Buy
+86,247
New +$444K ﹤0.01% 1838

Other funds holding CADL

Wellington Management Group's CADL Position: Q3 2026 in Review

Wellington Management Group increased its Candel Therapeutics (CADL) stake by 52% in Q3 2026, buying an estimated $1.19M and bringing the position to 313,005 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

Wellington Management Group first reported a position in CADL in Q2 2025 and has held it in 4 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Wellington Management Group held 313,005 shares of Candel Therapeutics worth $3.27M as of Q3 2026.
  • Wellington Management Group bought 107,260 Candel Therapeutics shares in Q3 2026, an estimated $1.19M.
  • Candel Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1513 holding.
  • Wellington Management Group first reported a position in Candel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.